Subtype Report: Diffuse Large B-Cell Lymphoma

Diffuse Large B-Cell Lymphoma (DLBCL) is a highly aggressive subtype of lymphoma, but if properly treated and managed the cure rate is as high as 70%. The prognosis for DLBCL improved significantly starting in 2000 when the monoclonal antibody rituximab was added to the standard chemotherapy of CHOP. A common and widely used treatment for DLBCL has been established as R-CHOP (CHOP with rituximab).

There is a myriad of ongoing research addressing the heterogeneity of DLBCL, better understanding the biology, as well as targeting molecular pathways and the advancement of therapeutic interventions. Moving forward, it will be necessary to investigate these targeted agents within patient populations who are most likely to benefit.

Understanding the importance of diagnosing the GCB and ABC sub groups of DLBCL and how that improves prognostication will be crucial to allow for the possibility of individualised risk-adapted therapy. DLBCL, as a subtype, requires independent reporting to ensure proper trending analysis and outcome reporting.


subtype report dlbcl 

Click here to view the report.


Global Database

Information by country, region and/or subtype on treatments, clinical trials and incidence/mortality rates.

Resource Library

Over 2,000 pieces of information on lymphoma diagnosis, treatment, research, support and lifestyle.

logo europe




The information on this website is for general use only. Please consult your physician if you think you may have lymphoma or
require more detailed information on the best course of treatment for you.

Our website does not host any form of advertisement. Last updated: 02/19/19. Copyright © 2018 Lymphoma Coalition. All rights reserved.